ORAGENICS INC 8-K

What Happened
Oragenics, Inc. (OGEN) filed a Form 8-K (Item 7.01) disclosing that the company’s CEO will use a presentation dated January 20, 2026, when speaking at the Sequire Investor Summit on January 20, 2026. The presentation is attached to the filing as Exhibit 99.1 and will also be available on Oragenics’ website under the “Presentations” tab in the “News and Media” section (www.oragenics.com). By filing the 8-K, the company states it is not admitting the presentation’s information is material solely because of Regulation FD and notes the presentation is summary information that should be read with the company’s SEC filings and other public announcements.

Key Details

• Filing type: Form 8-K, Item 7.01 (Regulation FD disclosure).
• Presentation: Exhibit 99.1, dated January 20, 2026, to be used at the Sequire Investor Summit on January 20, 2026.
• Availability: Presentation will be posted on Oragenics’ website under “Presentations” in “News and Media.”
• Company note: States no admission of materiality and no obligation to publicly update the presentation, though it may do so.

Why It Matters
This 8-K notifies investors where and when Oragenics’ management will present company information and provides the presentation for public review, which can affect investor understanding and market perceptions if the slides include new or company‑specific updates. The company’s Reg FD disclosure is meant to ensure broad, public access to the information, while explicitly leaving materiality determinations to be made in the context of its SEC filings and other public statements.